Introduction: The MAPK pathway comprises several key signaling components and
phosphorylation events that play a role in tumorigenesis. These activated kinases transmit …

In the past decade, major advances have been made in the understanding of melanoma.
New predisposition genes have been reported and key somatic events, such as BRAF …

The increased target specificity of epidermal growth factor receptor (EGFR) inhibitors
(EGFRIs) is associated with the reduction or abolition of nonspecific and haematopoietic …

Many human malignancies are associated with aberrant regulation of protein or lipid
kinases due to mutations, chromosomal rearrangements and/or gene amplification. Protein …

Vascular endothelial growth factor-2 (VEGFR-2) is considered one of the most important
factors in tumor angiogenesis, and consequently a number of anticancer therapeutics have …

Dermatologic adverse events to cancer therapies have become more prevalent and may to
lead to dose modifications or discontinuation of life-saving or prolonging treatments. This …

Purpose RAF inhibitors are effective against melanomas with BRAF V600E mutations but
may induce keratoacanthomas (KAs) and cutaneous squamous cell carcinomas (cSCCs) …

Contrary to initial expectations, angiogenesis inhibitors can cause toxicities in patients with
cancer. The toxicity profiles of these inhibitors reflect the disturbance of growth factor …

There has been a rapid emergence of numerous targeted agents in the oncology community
in the last decade. This exciting paradigm shift in drug development lends promise for the …

Molecularly targeted cancer therapies, such as small-molecule kinase inhibitors and
monoclonal antibodies, constitute a rapidly growing and an important part of the oncology …